PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7287481

[Modification of urinary pH through ascorbic acid].

C Bannwart·V Hagmaier·E Straumann·H Hofer·J P Vuillemier·G Rutishauser
View original source ↗Export metadata ↓

Abstract

The influence of orally administered ascorbic acid on the urinary pH of 10 healthy volunteers and 10 patients with infected urine was investigated. During a four-day period of investigation urinary pH and the concentration of ascorbic acid in the respective urines were measured five times a day. On the second and third day three times a dose of 2 g ascorbic acid was given, while the diet was under control all four days. A correlation between pH decrease and ascorbic acid concentration is only observed if the concentration of the latter is higher than 200 mg%. The mean decrease in urinary pH between days with ascorbic acid supply and days without is -0,16 pH units for the volunteers respectively -0,18 pH units for the patients. Therefore, vitamin C can not be recommended to lower the pH of alkaline urines.

Explore related subjects

Administration, OralAscorbic AcidHumansHydrogen-Ion ConcentrationUrinary Tract InfectionsUrineEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Bannwart, V Hagmaier, E Straumann, H Hofer, J P Vuillemier, G Rutishauser. 1981. [Modification of urinary pH through ascorbic acid].. https://pubmed.ncbi.nlm.nih.gov/7287481/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence.

PURPOSE: We evaluated the efficacy and safety of yohimbine and isoxsuprine or pentoxifylline in the management of vasculogenic erectile dysfunction. MATERIALS AND METHODS: A total of 20 patients diagnosed with arterial insufficiency and cavernous venous leakage by pharmacological penile duplex scanning underwent nonhormonal oral therapy. A randomized crossover study was performed using 5.4 mg. yohimbine plus 10 mg. isoxsuprine or 400 mg. pentoxifylline 3 times daily. Response to therapy was assessed by a sexual questionnaire and repeat penile duplex ultrasonography. RESULTS: No patient in either phase of the study in either group had a complete response to the oral regimen(s) and there was no improvement in the pre-injection or post-injection cavernous arterial peak systolic flow velocities or resistance indexes. CONCLUSIONS: Our study suggests that these oral agents, although well tolerated, were not effective in the management of these patients with mixed vasculogenic erectile dysfunction.

Administration, Oral↗